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Abstract: Spontaneous bacterial peritonitis (SBP) is one of the most common and 
life-threatening complications of cirrhosis. It occurs in 10% to 30% of patients admitted 
to hospital and recent studies tend to demonstrate that SBP incidence seems to be decreas-
ing in its frequency. A bacterial overgrowth with translocation through the increased 
permeable small intestinal wall and impaired defense mechanisms is considered to be the 
main mechanism associated with its occurrence. The Gram-negative aerobic bacteria are 
the major responsible for SBP episodes and Gram-positive bacteria, mainly Staphylococcus 
aureus, are being considered an emergent agent causing SBP. The prompt diagnosis of SBP is 
the key factor for reduction observed in mortality rates in recent years. The clinical diagnosis 
of SBP is neither sensitive nor speciﬁ  c and the search for new practical and available tools for 
a rapid diagnosis of SBP is an important endpoint of current studies. Reagent strips were con-
sidered a promising and faster way of SBP diagnosis. The prompt use of empirical antibiotics, 
mostly cefotaxime, improves signiﬁ  cantly the short-term prognosis of cirrhotic patients with 
SBP. The recurrence rate of SBP is high and antibiotic prophylaxis has been recommended in 
high-risk settings. Unfortunately, the long-term prognosis remains poor.
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Introduction
The relevance of infections in cirrhotic patients has been demonstrated since that 30% 
to 50% of patients have one type of infectious complication when admitted to hospital 
and 15% to 35% develop infections after being in hospital (Navasa et al 1999). Urinary, 
respiratory, ascitic ﬂ  uid infections and bacteremia are the most common infectious 
complications found mostly in Child-Pugh B and C cirrhotic patients (Krencker 1907; 
Brule et al 1939; Cachin 1955; Navasa et al 1999). Spontaneous bacterial peritonitis 
(SBP), reported by Caroli and Platteborse (1958) has had its importance increased since 
Kerr and colleagues (1963) and Conn (1964) published two papers about this cirrhosis 
complication almost simultaneously. Kerr and colleagues (1963) described 11 episodes 
of ascitic ﬂ  uid infection in 9 cirrhotic patients while Conn (1964) introduced the term 
“spontaneous bacterial peritonitis” for the ﬁ  rst time in English literature.
SBP is deﬁ  ned as the infection of ascitic ﬂ  uid without a contiguous source of intra-
abdominal infection (eg, intra-abdominal abscesses, intestinal perforation) and in the 
absence of intra-abdominal focus of inﬂ  ammation; cholecystitis or acute pancreatitis 
(Rimola et al 2000). SBP is one of the most frequent and life-threatening complications of 
patients with cirrhosis. Mortality rates have stayed constant in spite of the development of 
new antibiotic treatments and early diagnosis of SBP infection (Fernandez et al 2002). In 
their study, Singh and colleagues (2003) described the mortality rate of SBP in two differ-
ent cohorts over a ten-year period and did not ﬁ  nd any difference between the cohorts. The 
in-hospital mortality rate can reach 30% in spite of infection control measures; mortality 
being generally due to complications such as acute variceal bleeding, development of the Therapeutics and Clinical Risk Management 2008:4(5) 920
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hepato-renal syndrome, or progressive liver failure (Sette et al 
1986; Hurwich et al 1993; Mattos 1994; Jeffries et al 1999; 
Thuluvath et al 2001; Fernandez et al 2002).
The incidence of SBP has been estimated in 10% to 30% 
of unselected patients admitted to hospital (Hurwich et al 
1993; Rimola et al 1995; Jeffries et al 1999; Thuluvath et al 
2001; Fernandez et al 2002; Singh et al 2003). Nevertheless, 
recent studies tend to demonstrate that SBP incidence seems 
to be decreasing (Sette et al 1986). A recent multicenter study 
carried out in 70 different centers observed an incidence of 
SPB of 5.5% (Nousbaum et al 2007). We studied prospec-
tively 200 samples of ascitic ﬂ  uid of 106 cirrhotic patients 
and detected SBP in 11% of the studied population in both 
inpatient and outpatient settings. In asymptomatic outpatients 
that were submitted to therapeutic paracenteses the incidence 
of SBP seems to be lower and is estimated at 0.57% to 3.5% 
(Evans et al 2003; Castellote et al 2008).The outcome of SBP 
in this group of patient has been demonstrated to be better 
than in hospitalized cirrhotic patients (Evans et al 2003). The 
probability of development of the ﬁ  rst episode of SBP over a 
one-year period in patients with end-stage-liver disease and 
ascites is around 10%.
The mainstay of SBP physiopathology seems to be the 
association of bacterial translocation with the decrease in host 
immune system defenses. It has been demonstrated, ﬁ  rstly in 
animal models with ascites and later in cirrhotic patients, that 
passage of intestinal bacteria from the gut to extra intestinal 
sites could be increased (Garcia-Tsao et al 1995; Cirera et al 
2001). Studies using oral nonabsorbable antibiotics rein-
force the hypothesis that exist a causal relationship between 
bacterial translocation and the occurrence of SBP. The use 
of these antibiotics decreases the development of SBP and 
other spontaneous infections in cirrhotic patients (Rimola 
et al 1985; Ginès et al 1990; Soriano et al 1992).
The disturbance in small intestinal motility and the 
presence of hypochlorydria has been demonstrated to occur 
in cirrhotic patients and seems to be responsible for the 
bacterial overgrowth commonly observed in these patients 
(Bauer et al 2001). The actual role of intestinal overgrowth 
in the pathogenesis of SBP has not yet been settled. Chang 
and colleagues (1998) demonstrated that the prevalence of 
bacterial overgrowth was higher in patients with a history of 
SBP associated to disturbances in small intestinal motility. 
On the other hand, Bauer and colleagues (2001) were not able 
to conﬁ  rm this hypothesis in their investigation.
These bacteria are translocated through the intestinal 
wall, which has its permeability altered by the portal hyper-
tension; in consequence they reach the mesenteric lymph 
nodes. After that, they move to the systemic circulation until 
they contact the ascitic ﬂ  uid. Other sites than gut have been 
demonstrated to originate bacteria seeding. These could be 
represented by pneumococcal sepsis, cellulites, urinary tract 
and dental infections (Chang et al 1998; Evans et al 2003).
Once the bacteria reach the ascitic ﬂ  uid, the host immune 
defense is responsible for the occurrence or not of SBP. The 
macrophages are the ﬁ  rst line of defense of the peritoneal 
cavity and the impairment in phagocytic activity of reticu-
lendothelial system (RES) can cause a prolonged bacteremia. 
The liver is the largest organ of the RES and this dysfunction 
evidently imposes infectious risks. The next step of immune 
system defense is the activation of complement with further 
release of cytokines. The polymorphonuclear neutrophilic 
leukocytes (PMNs) try to destroy the bacteria by entering in 
the peritoneal cavity. The dysfunction of PMNs and the low 
levels of complement, both by decreasing in liver produc-
tion associated to increased consumption as an acute phase 
response, are commonly observed in cirrhosis and seem to 
contribute to the conversion of ascitic ﬂ  uid colonization into 
SBP (Runyon et al 1985; Guarner et al 1995; Homman et al 
1997). For such reasons cirrhosis is considered one of the 
most common current forms of acquired immune deﬁ  ciency. 
More recently, Christou and colleagues (2007) indicated 
bacteremia/sepsis, respiratory and urinary tract infection, 
meningitis, endocarditis, phlegmonous colitis and hepatic 
abscess as other common speciﬁ  c infectious complications 
beyond SBP, in hepatic cirrhosis.
Etiology
The Gram-negative bacteria are largely responsible for SBP 
episodes and were isolated in 80% of the cases of SBP that 
were culture-positive (Fernandez et al 2002). Escherichia 
coli, streptococci (mostly pneumococci), and Klebsiella cause 
most episodes of spontaneous bacterial peritonitis in patients 
who are not receiving selective intestinal decontamination 
(Garcia-Tsao 1992). On the other hand, in patients who 
have been treated with antibiotic prophylaxis (quinolones) 
the incidence of Gram-positive bacteria has increased and 
Staphylococcus aureus is being considered an emergent 
agent causative of SBP (Cholongitas et al 1995; Llovet 
et al 1997; Almeida et al 2007). The incidence of antibiotic 
resistance in Gram-negative bacteria is increasing mostly 
due to the widespread employment of quinolones for SBP 
prophylaxis. The frequency of multiple drug-resistant bac-
teria has increased from 8.3% to 38.5% while at same time 
fungal etiology has been noticed to range from 4% to 18.7% 
(Singh et al 2003).Therapeutics and Clinical Risk Management 2008:4(5) 921
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Some authors have pointed the existence of several risk 
factors associated with SBP. The ascitic total protein has 
been recognized as predictive of SBP development and the 
risk is higher when values of less than 1 g/dL of total protein 
are found (Runyon 1986; Llach et al 1992) and some experts 
recommend primary prophylaxis (Frazee et al 2005). Others 
factors that have been pointed out are serum total bilirubin 
concentration above 2.5 mg/dL, variceal bleeding, and a prior 
episode of SBP (Andreu et al 1993; Guarner et al 1999).
Diagnosis
The prompt diagnosis of SBP is the key aspect for the reduc-
tion in its mortality rates in recent years. The clinical diag-
nosis of SBP is neither sensitive nor speciﬁ  c. The signs and 
symptoms are likely to be insidious and the clinical picture of 
generalized peritonitis is uncommon. Almost 13% of patients 
have no signs of infection. The most frequent symptoms 
associated with SBP are abdominal pain and/or tenderness, 
fever or new development of encephalopathy. In our study, 
the disturbing in mental state was the most common feature 
related to SBP (52%), followed by abdominal pain (24%) and 
fever (21%). Change in bowel movements is also described 
and diarrhea can herald SBP. The occurrence of paralytic 
ileus, hypotension, and hypothermia are always signs sug-
gesting advanced infection and carries on a poor prognosis. 
The blood samples could reveal leukocytosis, acidosis, and 
the worsening of renal function. In fact blood cultures are 
positive in a half of the episodes of SBP and should be done 
in order to maximize the possibilities of isolating an infecting 
pathogen (Runyon et al 1987; Rimola et al 2000).
Paracentesis should be done anytime a suspicion of SBP 
is considered and ascitic ﬂ  uid analysis is the mainstay of 
SBP diagnosis. The performance of paracentesis is safe and 
although almost 70% of cirrhotic patients have an abnormal 
prothrombin time, less than 1 in every 1000 procedures may 
complicate with hemorrhagic events. The risk of such com-
plication should not be a reason to avoid it, even in patients 
with obvious disseminated intravascular coagulopathy or 
clinically apparent ﬁ  brynolisis. Despite the risks the method 
is worth considering because of its beneﬁ  ts.
The PMN count – greater than 250 cel/mm3 – and the 
yield of cultures of the ascitic ﬂ  uid are considered the gold 
standard for the diagnosis of SBP (Rimola et al 2000). Ascitic 
ﬂ  uid should be cultured at bedside in blood culture bottles, as 
soon as the paracentesis is done, as ﬁ  rstly demonstrated by 
Runyon and colleagues (1987) in order to achieve a positive 
result in almost 91% of the samples. Although many studies 
have conﬁ  rmed Runyon’s results, Brazilian studies could 
not reach this accuracy in isolating SBP pathogens (Sette 
et al 1986; Mattos 1994; Figueiredo et al 1999; Coral et al 
2002). In our studied group of patients, ascitic ﬂ  uid culture 
was positive in only 28.5% of samples although it has been 
cultured at bedside and in accordance to previously described 
standard techniques. Therefore, the ascitic ﬂ  uid culture has 
some shortcomings. First of all, the results of culture are not 
readily available, which postpones the diagnosis and treat-
ment of the infection. Secondly, one of the most frequent 
variants of ascitic ﬂ  uid infection is culture-negative neutro-
cytic ascites, which occurs in approximately 30% to 50% 
of patients (Sette et al 1986; Runyon et al 1987; Figueiredo 
et al 1999; Coral et al 2002).
Not only does the PMN count seems to be accurate 
enough to determine which patients need to start empiric 
antibiotic therapy but they have also been considered the 
easiest way to establish the early diagnosis of SBP (Rimola 
et al 2000; Moore et al 2003; Runyon 2004). Although the 
total cell count of polymorfonuclear neutrophilic leukocyte 
can be easily performed and have a good sensibility for 
SBP diagnosis, it is not always promptly performed and 
depends on the interest and skills of the medical technician. 
This technique could also be not available in every setting 
(eg, small hospitals). Hence, other ways of establishing SBP 
diagnoses are under assessment. In spite of the accuracy of 
automated cell counts in this scenario, it needs to be validated 
and requires technology not yet widely available (Angeloni 
et al 2003).
The use of reagent strips for the prompt diagnosis of 
urinary tract infections is well recognized. It is also applied 
in the diagnosis of other forms of biologic ﬂ  uid infections 
such as pleural effusions, meningitides, and spontaneous 
bacterial empyema (Moosa et al 1995; Azoulay et al 2000; 
Castellote et al 2005). The background of those reagents 
strips is granulocytes esterase activity. This enzyme has 
been found in ascitic ﬂ  uid and is responsible for the release 
of 3-hydroxy-5-phenyl-pyrrole, which causes a color change 
in an azo dye (purple). The accuracy of those strips for 
urinary tract infections had been revised in a meta-analysis 
with a sensibility range from 56% (in emergency setting) to 
87% (in outpatient setting) (Devillé et al 2004). This wide 
discrepancy could be explained mostly by the clinical set-
ting in which it had been used. Other studies have addressed 
this issue in an SBP scenario and the results showed strips 
as a promising method with both sensibility and speciﬁ  city 
reaching almost 100% (Vanbiervliet et al 2002; Castellote 
et al 2003; Thèvenot et al 2004; Braga et al 2006; Torun 
et al 2007). Since those initial studies others have evaluated Therapeutics and Clinical Risk Management 2008:4(5) 922
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different brands of strips achieving good diagnostic accuracy 
too (Castellote et al 2003; Sarwar et al 2005; Wisniewski et al 
2005; Rerknimitr et al 2006).
Unfortunately, a recent prospective multicenter trial that 
enrolled 70 centers has evaluated the use of Multistix 8SG 
(Bayer HealthCare, São Paulo, Brazil), both in outpatient 
and inpatient settings and could not conﬁ  rm the previous 
results (Nousbaum et al 2007). In this study sensibility was 
45.3%, speciﬁ  city 99.2%, positive predictive value 77.9% 
and negative predictive value 96.9%. The test performance 
was similar to the observed in our recently published study 
using Multistix 10SG (Ribeiro et al 2007). Hence, the results 
of these studies conﬁ  rm the excellent speciﬁ  city of these 
strips, but also make obvious its poor sensibility, placing 
this test as a supportive tool in SBP diagnosis that could not 
replace the cytological exam.
Moreover the diagnostic accuracy of those strips seems 
to differ according to the brand that had been used. Kim and 
colleagues (2005) studied the use of two brands of reagent 
strips, Uriscan (BioSys Laboratories, La Canada, CA, USA) 
and Multistix 10SG for SBP diagnosis and found different 
results in sensibility and speciﬁ  city. The results obtained 
with Uriscan were better than those observed with Multistix 
10SG. Sapey and colleagues (2005a, 2005b) also used dif-
ferent brands, Nephur Test (Roche Diagnostics GMBH, São 
Paulo, Brazil) and Multistix SG, and found that Nephur Test 
outperfomed Multistix SG.
The largest published study to date used Multistix 8SG 
(Nousbaum et al 2007), so it seems reasonable to carry out 
new research comparing different brands in a large number 
of patients to clarify this issue.
Treatment
The development of new antibiotics and the possibility of 
an earlier diagnosis of SBP have dramatically changed the 
natural history of its resolution from 25% before 1980 to 
70%–90% in the last few years (Navasa et al 1999).
Felizart and colleagues (1985) demonstrated the ﬁ  rst 
evidence of cefotaxime efﬁ  ciency for SBP. The comparison 
of cefotaxime with the association of ampicillin and tobrami-
cin showed a higher rate of infection resolution with neither 
nephrotoxicity nor super infection in those treated with 
cefotaxime. Since that, cefotaxime is being considered the 
treatment of choice for SBP and the dosage recommended 
is 2 g every 8h (Rimola et al 1995, 2000; Moore et al 2003). 
However, one study compared two different doses of cefo-
taxime in 143 patients with SBP, using 2 g every 6 h and 
2 g every 12 h (Rimola et al 1995). The rate of infection 
resolution was the same in both groups (77% versus 79%). 
The interval between doses could be less frequent, mainly 
in patients with renal function impairment. A similar third-
generation cephalosporin, as ceftriaxone 2 g intravenous 
daily, is considered a reasonable choice for suspected SBP, 
in empiric therapy, while the result of ascitic ﬂ  uid culture is 
not known (Javid et al 1998).
Other antibiotics have been studied and are an alternative 
for SBP treatment, but caution should be taken in avoid-
ance of those that have nephrotoxicity and increased risk of 
multiresistant bacteria development. The use of amoxicil-
lin/clavulanate seems to be secure and efﬁ  cient alternative 
(Grange et al 1990).
Oﬂ  oxacin, an oral quinolone, has been demonstrated to 
be as effective as intravenous cefotaxime in treatment of 
uncomplicated patients with SBP, but the only drawback of 
this treatment is the recent observation of quinolone-resistant 
organism emergence (Navasa et al 1996; Moore et al 2003). 
Intravenous ciprofloxacin starting therapy followed by 
another oral antibiotic has also been demonstrated to produce 
good results in infection control (Terg et al 2000).
The increase in Gram-positive cocci as the causative 
pathogen of SBP has been attributed to the use of norﬂ  oxacin 
prophylaxis and invasive procedures that patients are submitted 
(Llovet et al 1997; Cholongitas et al 2005). Nevertheless, 
few data exist regarding the susceptibility of these agents 
(Navasa et al 2002; Almeida et al 2007). The occurrence of 
methicillin-resitant S. aureus to quinolone and trimethoprim-
sulfamethoxazole is being shown (Almeida et al 2007).
One of the most important predictor of death in SBP is 
renal function impairment that occurs in almost 30%–40% 
of patients. The use of plasma volume expansion, such as 
albumin, decreases the risk of death from 10% to 30% (Bass 
1999; Runyon 1999; Sort et al 1999). The incidence of 10% 
in-hospital mortality is the lowest reported in literature. The 
use of albumin is based on the theory that plasma volume 
expansion could attenuate the hemodynamic changes observed 
in those patients (Ginès et al 1997). Albumin infusion has been 
recommended in a 10 dosage of 1.5 g/kg of body weight at 
diagnosis, followed by 1 g/kg of body weight on day three 
(Salerno et al 2007). Although it is a currently practice, based 
on a single study that demonstrated lower mortality rates and 
lower occurrence of renal impairment, further controlled 
studies should be done to conﬁ  rm these ﬁ  ndings.
SBP Prophylaxis
The SBP recurrence rate is high; demonstrated in 40%–70% 
of patients after one year of development of the ﬁ  rst episode Therapeutics and Clinical Risk Management 2008:4(5) 923
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(Tito et al 1988). Consequently, the secondary prophylaxis 
treatment should be done in this setting. The mortality rates 
could be signiﬁ  cantly reduced to 20% in patients submitted 
to the use of oral norﬂ  oxacin (400 mg/day) and the approach 
advised by the International Club of Ascites seems to be cost-
effective (Moore et al 2003). The use of weekly quinolones 
could not achieve this efﬁ  cacy and the emergence of resistant 
pathogens seems to be an actual problem.
The recommendation of primary prophylaxis is not well 
deﬁ  ned and there is no consensus about the matter. The risk 
of increased Gram-positive resistance in those who use pro-
longed antibiotic prophylaxis has been considered a problem 
to recommend it and some authors disagree of this strategy, 
limiting the antibiotic employment to in-hospital period 
(Novella et al 1997). Factors that have been associated with 
increased SBP incidence are: low protein ascitic ﬂ  uid, low 
platelet counts (98.000 mm3) and high serum bilirubin 
levels (3.3 mg/dL) (Guarner et al 1999). Further studies are 
necessary to ﬁ  gure out the actual factors, which predispose 
SBP occurrence and how to deal with them. Fernández and 
colleagues (2007) have recently demonstrated the efﬁ  cacy of 
norﬂ  oxacin in preventing SBP as its importance in the delay 
of hepatorenal syndrome.
On the other hand, the role of SBP prophylaxis in 
patients with acute intestinal bleeding is renowned. 
A meta-analysis evaluated the use of antibiotic prophylaxis 
for patients with gastrointestinal hemorrhage and reports 
a signiﬁ  cant reduction in the incidence of SBP and an 
improvement in short-term survival was also demonstrated 
(Bernard et al 1999). The decrease in the rate of variceal 
rebleeding could be observed in another recent study 
(Hou et al 2004). The International Ascites Club recom-
mends the use of norﬂ  oxacin 400 mg every 12 h in every 
patient admitted to hospital with gastrointestinal bleeding 
whenever ascites is present or not (Moore et al 2003). 
Ciproﬂ  oxacin 500 mg every 12 h is also recommended by 
the British Society of Gastroenterology guidelines (Jalan 
and Hayes 2000).
The increased emergence of multiresistant pathogens, 
mostly quinolone-resistant bacteria, has demanded the 
search for alternative ways of SBP prophylaxis. Other anti-
biotics such as amoxicillin-clavulanate and trimethoprim-
sulfamethoxazole are proved to be efﬁ  cient (Lontos et al 
2007). Other forms of SBP have being studied as the use 
of cisapride and propranolol that were evaluated in order to 
increase the intestinal motility and consequently decrease 
the bacterial translocation (Pardo et al 2000; Perez-Pararmo 
et al 2000). The studies in animal models reveal the efﬁ  cacy 
of such drugs, but the usage of them in humans needs to 
be demonstrated. The economic issue of long-term anti-
biotic prophylaxis was evaluated by two different studies 
that proved this approach as being cost-saving in high-risk 
patients. A recent study (Fernández et al 2006) calls attention 
to the higher effectiveness of ceftriaxone in comparison to 
oral norﬂ  oxacin in the prophylaxis of bacterial infections in 
patients with advanced cirrhosis and hemorrhage. Another 
relevant fact is the role of tumor necrosis factor-α (TNF-α) 
in SBP and its therapy since that in the experimental model of 
CCl4-induced rat with cirrhosis and ascitic ﬂ  uid, anti-TNF-α 
mAb administration decreases the incidence of bacterial 
translocation, in a TNF-α/sTNF-α receptor-independent 
manner, without increasing the risk of systemic infections 
(Francés et al 2007).
Actually, the importance of this life-threatening condition 
is being widening studied and the early diagnosis associated 
with better treatments with drugs that have less nephrotoxic-
ity have dramatically changed the current scenario of SBP. 
The widespread use of broad-spectrum antibiotics needs to 
be stopped and further studies on alternatives forms of SBP 
prophylaxis are waited for the perfect management of such 
hazardous cirrhosis complication.
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